185 related articles for article (PubMed ID: 33107192)
1. Small-Molecule Inhibition of the uPAR ⋅ uPA Interaction by Conformational Selection.
Xu D; Bum-Erdene K; Leth JM; Ghozayel MK; Ploug M; Meroueh SO
ChemMedChem; 2021 Jan; 16(2):377-387. PubMed ID: 33107192
[TBL] [Abstract][Full Text] [Related]
2. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
3. Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.
Liu D; Xu D; Liu M; Knabe WE; Yuan C; Zhou D; Huang M; Meroueh SO
Biochemistry; 2017 Mar; 56(12):1768-1784. PubMed ID: 28186725
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
5. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
6. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.
Xu D; Bum-Erdene K; Si Y; Zhou D; Ghozayel MK; Meroueh SO
ChemMedChem; 2017 Nov; 12(21):1794-1809. PubMed ID: 28960868
[TBL] [Abstract][Full Text] [Related]
7. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
Khanna M; Wang F; Jo I; Knabe WE; Wilson SM; Li L; Bum-Erdene K; Li J; W Sledge G; Khanna R; Meroueh SO
ACS Chem Biol; 2011 Nov; 6(11):1232-43. PubMed ID: 21875078
[TBL] [Abstract][Full Text] [Related]
8. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.
Gårdsvoll H; Kjaergaard M; Jacobsen B; Kriegbaum MC; Huang M; Ploug M
J Biol Chem; 2011 Dec; 286(50):43515-26. PubMed ID: 22025616
[TBL] [Abstract][Full Text] [Related]
9. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
10. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Reuning U; Sperl S; Kopitz C; Kessler H; Krüger A; Schmitt M; Magdolen V
Curr Pharm Des; 2003; 9(19):1529-43. PubMed ID: 12871066
[TBL] [Abstract][Full Text] [Related]
12. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
Mani T; Wang F; Knabe WE; Sinn AL; Khanna M; Jo I; Sandusky GE; Sledge GW; Jones DR; Khanna R; Pollok KE; Meroueh SO
Bioorg Med Chem; 2013 Apr; 21(7):2145-55. PubMed ID: 23411397
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides.
Bürgle M; Koppitz M; Riemer C; Kessler H; König B; Weidle UH; Kellermann J; Lottspeich F; Graeff H; Schmitt M; Goretzki L; Reuning U; Wilhelm O; Magdolen V
Biol Chem; 1997; 378(3-4):231-7. PubMed ID: 9165076
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the urokinase receptor in a ligand-free form.
Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
[TBL] [Abstract][Full Text] [Related]
16. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
17. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
18. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
19. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
[TBL] [Abstract][Full Text] [Related]
20. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
